Hema

Hematology Analyzers Simple, Sophisticated Technology Serving All Patients

Some form of electronic hematology analyzer is found at the center of most clinical laboratories. A blood cell count is usually the first screening test used to assess general health, rule out anemia or infection, and monitor cancer patients during the course of chemotherapy. It is difficult to imagine medical...

Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

C-reactive protein (CRP) is an acute-phase protein that has long been recognized as a marker of systemic inflammation. CRP measurement can complement a range of diagnostic markers to monitor infection and direct treatment. However, as economic rationalization...

Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced that additional Phase 2 clinicaltrial results for Hematide(TM) were presented at the European RenalAssociation-EDTA Congress being held in Barcelona, Spain by Iain C.Macdougall, M.D., a Hematide investigator from Kings College,London. Dr. Macdougall's poster included data in previously-treateddialy...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

-LymphoStat-B(R) significantly reduced signs and symptoms of SLEdisease at 52 Weeks and demonstrated durable clinical andbiological activity at 76 weeks- ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today announced the presentation of Phase 2trial data demonstrating that LymphoStat-B(R) (belimumab)significantly reduced disease activity across multiple...

Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial

GERMANTOWN, Md., June 13, 2007 /PRNewswire-FirstCall/ -- AvalonPharmaceuticals, Inc. , today announced that it is will provide anupdate on the Phase I clinical trial of AVN944 in hematologicmalignancies on Tuesday, June 19, 2007, after the close of the U.S.financial markets. The Company will also host a conference call onWednesday, June 20, 2007 at 8 a.m. Eastern Time. Interestedinvestor...

Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification

SALT LAKE CITY, UT, June 11, 2007 (MARKET WIRE via COMTEX NewsNetwork) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (<a target="_blank" href="http://www.myriad.com/">www.myriad.com )announced today that it presented a mathematical comparison of a"Staggered Start" and a "Randomized Withdrawal" clinical trialdesign with a "Natural History Staggered Start" clinical trialdesign at the Alzheime...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

Interim Data from Phase 1 Clinical Trial of SNS-595 in AcuteLeukemia Demonstrates Additional Clinical Activity SOUTH SAN FRANCISCO, Calif., June 11, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presentedpositive data from clinical studies of two of the company'santi-cancer product candidates, SNS-595 and SNS-032, at the 12thCongress of the European Hematology Association (E...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

HDAC Inhibitor MGCD0103 Demonstrates substantial Response Ratein Two Clinical Trials Clinical Data Presented on Pilot Pharmacokinetic Study of OralAzacitidine Exelixis Reports Integrated Data From Phase II Clinical Trialsof XL999 at ASCO Clinical Data Reported on Vidaza in Hematologic Malignancies andAdva...

Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association

SOUTH SAN FRANCISCO, Calif., June 01, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. todayannounced that the company will present data from ongoing clinicalstudies of SNS-595 and SNS-032 at the 12th Congress of the EuropeanHematology Association (EHA) being held June 7-10, 2007 in Vienna,Austria. Presentations will include updated interim data from thecompany's Phase...

Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced results to date from two separatePhase 2 clinical trials of Hematide(TM) in dialysis andnon-dialysis chronic kidney disease (CKD) patients. The data showedthat in treatment naive, non-dialysis patients Hematide couldcorrect anemia when administered monthly at an appropriate dose.Similarly, the data...

EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers

ROCKVILLE, Md., April 19, 2007 /PRNewswire-FirstCall/--EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,today announced the presentation of preclinical results for MKC-1,its novel cell cycle inhibitor. The data were presented by EntreMedscientists at the American Association for Cancer Research (AACR)Ann...

Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 12, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced that results available from its Phase2 clinical trial of Hematide(TM) dosed monthly in dialysis patientswere presented this week at the National Kidney Foundation (NKF)2007 Spring Clinical Meeting. The results from thismaintenance-switch trial in patients previously treated withthree-times weekly E...

IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation

Animal Data Shows Prolonged Survival AND Increased PlateletConcentrations SCOTTSDALE, Ariz., March 08, 2007 /PRNewswire-FirstCall/ --ImmuneRegen BioSciences, a wholly-owned subsidiary of IRBioSciences Holdings, Inc. announced today that ongoing analysis ofdata acquired from previously performed animal efficacy studies hasrevealed evidence that ImmuneRegen's developmental stage product,Ra...